Acrux ( (AU:ACR) ) has shared an announcement.
Acrux, in partnership with TruPharma, has launched Dapsone 7.5% Gel in the United States, a topical prescription medicine for treating acne vulgaris in children aged 9 and older. This product is uniquely marketed in a tube presentation, differentiating it from competitors’ pump bottle packaging, and is manufactured in the U.S. The launch underscores Acrux’s strategic capability to develop and commercialize its pharmaceutical pipeline, with the U.S. market for similar products generating over $43 million in sales annually.
More about Acrux
Acrux is a specialty pharmaceutical company with a focus on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, Acrux has successfully marketed products worldwide, particularly in the United States, leveraging its skilled workforce and facilities to bring affordable generic products to market. The company is open to collaboration and commercial partnerships.
Average Trading Volume: 243,670
Technical Sentiment Signal: Sell
Current Market Cap: A$9.37M
For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.